SCHEMBL4874102

SCHEMBL4874102

O=CN1CCCOCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11841381 0.92
SCHEMBL7321 0.92
SCHEMBL25224342 0.90 TSHR (0.43)
Hydrochloric Acid SCHEMBL3855161 0.89 CA12 (0.38)
SCHEMBL16607618 0.89 SMN1; SMN2 (0.39)
SCHEMBL13434243 0.89 SMN1; SMN2 (0.39)
Hydrochloric Acid SCHEMBL5012159 0.89
SCHEMBL27693198 0.86 CA12 (0.36)
Formic Acid SCHEMBL17969575 0.84 RECQL (0.37)
Dimethylamine SCHEMBL27638726 0.82 RECQL (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3723754-B1 IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME LLC (US) 2026-05-13 EP claimed
CN-114761404-B Substituted bicyclic heteroaryl compounds 百时美施贵宝公司 2025-02-21 CN claimed
US-20250049814-A1 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2025-02-13 US claimed
US-12194051-B2 5-azaindazole derivatives as adenosine receptor antagonists MERCK PATENT GMBH (DE) 2025-01-14 US claimed
EP-3693360-B1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICALS CO (JP) 2023-12-13 EP claimed
EP-4041730-A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS Bristol-Myers Squibb Company (US) 2022-08-17 EP claimed
CN-114761404-A Substituted bicyclic heteroaryl compounds 百时美施贵宝公司 2022-07-15 CN claimed
CN-114269730-A 5-heteroaryl-pyridin-2-amine compounds as neuropeptide FF receptor antagonists 多曼治疗学公司 2022-04-01 CN claimed
EP-3693360-A1 HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2020-08-12 EP claimed
EP-3176163-B1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT IAC IN NAT UNIV CHUNGNAM (KR) 2019-04-17 EP claimed
US-20170152268-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT MOTHER'S PHARMACEUTICAL CO., LTD. (KR) 2017-06-01 US claimed
US-20250049814-A1 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2025-02-13 US disclosed
US-12194051-B2 5-azaindazole derivatives as adenosine receptor antagonists MERCK PATENT GMBH (DE) 2025-01-14 US disclosed
CN-112912142-B 5-Azaindazole derivatives as adenosine receptor antagonists 默克专利股份公司 2024-08-16 CN disclosed
US-11939327-B2 Heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-03-26 US disclosed
EP-2424843-B1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES NOVARTIS AG (CH) 2014-03-26 EP disclosed
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-20090275555-A1 Substituted indole ligands for the ORL-1 receptor BRANE DISCOVERY S.R.L. (IT) 2009-11-05 US disclosed
US-20090275555-A1 Substituted indole ligands for the ORL-1 receptor BRANE DISCOVERY S.R.L. (IT) 2009-11-05 US disclosed
US-20080280906-A1 Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders ASTRAZENECA AB (SE) 2008-11-13 US disclosed